Alder names Paul Cleveland to board
This article was originally published in Scrip
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, has named Paul B. Cleveland to its board of directors. Cleveland currently serves as president and CEO of Celladon Corporation and previously served as Celladon's president and chief financial officer. He is also a member of the board and chair of the audit committee of Sangamo Biosciences, Inc.